Abstract
Iterum Therapeutics is launching with a focus on differentiated anti-infectives. The firm raised $40 million in a first round of venture capital financing and has licensed a compound from what it calls a top-tier multinational company. Iterum’s CEO, Corey Fishman, was an executive with the antibiotics firm Durata Therapeutics, which was sold to Actavis in 2014. Meanwhile, the pain specialist Centrexion Therapeutics just acquired a pipeline of non-opioid pain treatments from Boehringer Ingelheim. Headed by former Pfizer CEO Jeff Kindler, Centrexion has raised $58 million to date.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
